{"id":"W1674196795","doi":"10.1016/s1473-3099(15)00152-8","title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Efavirenz; Emtricitabine; Regimen; Medicine; Dolutegravir; Nucleoside Reverse Transcriptase Inhibitor; Internal medicine; Raltegravir; Reverse-transcriptase inhibitor; Pharmacology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001824946,0.002061809,0.003264156,0.0005239437,0.0004300503,0.001309852,0.001115772,0.002193461,0.007640004],"category_scores_gemma":[0.001942805,0.0008444641,0.001784746,0.0004635915,0.001524565,0.001710504,0.0005351861,0.004871452,0.001775252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008360592,"about_ca_system_score_gemma":0.001057435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001305674,"about_ca_topic_score_gemma":0.002783219,"domain_scores_codex":[0.9992566,0.0004056328,0.00003379124,0.0001154452,0.00004488132,0.0001435598],"domain_scores_gemma":[0.9990501,0.0003245081,0.0001375997,0.00008002626,0.00004576977,0.0003620934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9768401,0.004887762,0.0002634622,0.0003772976,0.0003629601,0.0000262616,0.00005788606,0.0002732007,0.001886564,0.00009489217,0.0005229944,0.01440646],"study_design_scores_gemma":[0.9348513,0.06311804,0.0008358406,0.00002936858,0.0001673024,0.00002725098,0.00002270103,0.0002001996,0.0002184125,0.0001110561,0.0004048219,0.00001376086],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878783,0.004084983,0.0006281563,0.0007005479,0.0006151249,0.002088688,0.001019645,0.0002060671,0.002778537],"genre_scores_gemma":[0.9829999,0.003747736,0.001667569,0.001343084,0.000548697,0.00238781,0.001345883,0.00005367216,0.005905673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007640004,"threshold_uncertainty_score":0.02555835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01747817052545608,"score_gpt":0.2684220902275357,"score_spread":0.2509439197020796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}